Neurocrine Biosciences Inc (NBIX)
NasdaqGS · Price as of · Nasdaq Real Time Price
- Analysts27
- Implied upside+38.7%
- Target range$165.00 to $249.00
- EPS expected$2.72 +25%
- A year ago$2.17
- Revenue expected$1.04B +31%
- Estimate range$2.07 to $3.39
SEC filings
| Form | Filed | Description |
|---|---|---|
| 4 | August 5, 2026 | FORM 4 |
| S-8 | July 31, 2026 | S-8 |
| 8-K/A | July 31, 2026 | 8-K/A |
| 10-Q | July 31, 2026 | 10-Q |
| 4 | July 30, 2026 | FORM 4 |
| 8-K | July 30, 2026 | 8-K |
| SCHEDULE 13G/A | July 27, 2026 | View on EDGAR |
| 4 | July 13, 2026 | FORM 4 |
Frequently asked questions
When does NBIX report earnings?
Neurocrine Biosciences Inc (NBIX) is scheduled to report quarterly results on October 28, 2026 (estimated). The 16-analyst consensus is $2.72 per share on revenue of $1.04B for the quarter ending September 30, 2026, against $2.17 and $794.9M a year earlier. It has beaten the consensus EPS estimate in 3 of the last four quarters. The date is an estimate from past reporting patterns and can move until the company confirms it.
What do analysts expect for NBIX?
27 analysts cover Neurocrine Biosciences Inc (NBIX). The consensus rating is Strong buy. The average price target is $211.57, in a range of $165.00 to $249.00.
Are insiders buying or selling NBIX?
We have no qualifying Form 4 insider purchases or sales on record for Neurocrine Biosciences Inc (NBIX). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Where can I see NBIX SEC filings?
Recent filings are listed on this page, newest first. The latest is a 4 filed August 5, 2026.